MIRA MIRA Pharmaceuticals, Inc.

0.3683USD-37.68%Mkt Cap: 15.48M USDP/E: 36.83

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.…

Institutional holders19 on file

Key Statistics

Company
Market Cap15.48M USD
Enterprise Value18.06M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-10.44M USD
Revenue/Share—
Last Price0.3683 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees—
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - General
ISIN—
Valuation
P/E (Trailing)36.83
P/E (Forward)-0.90
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B2.26
EPS (TTM)-1.17 USD
EPS (Forward)-0.41 USD
52W Range
0.34002% of range1.690
52W High1.690 USD
52W Low0.3400 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-100.49%
ROA-94.13%
ROIC—
ROCE-100.98%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-4.66M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-6.51%
Net Debt-8.11M USD
Net Debt/EBITDA—
Net Debt/FCF—
Balance Sheet
Debt/Equity—
Current Ratio200.08
Quick Ratio198.75
Book Value/Sh0.25 USD
Cash/Share0.19 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)3.500 USD
Upside (mean)+850.3%
Target Range3.500 USD – 3.500 USD
# Analysts1
Ownership
Shares Out.42.02M
Float38.69M
Insiders30.58%
Institutions6.27%
Short Interest
Short Ratio1.7d
Short % Float0.97%
Short % Out.0.67%
Shares Short282.32K
Short (prev mo.)408.84K
Technical
SMA 500.6963 (-47.1%)
SMA 2000.9214 (-60.0%)
Beta1.65
S&P 52W Chg12.08%
Avg Vol (30d)126.36K
Avg Vol (10d)85.80K
Technical Indicators
RSI (14)26.4
MACD-0.0322
MACD Signal-0.0273
MACD Hist.-0.0049
BB Upper0.7057 USD
BB Middle0.5753 USD
BB Lower0.4449 USD
BB Width45.33%
ATR (14)0.0692 USD
Vol Ratio (20d)4.63x

About MIRA Pharmaceuticals (NASDAQ: MIRA)

›

MIRA Pharmaceuticals (NASDAQ: MIRA) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - General industry, part of the Healthcare sector.

The shares were at 0.3683 USD on 19 November 2026, down 74.4% over 52 weeks. Its 52-week range is 0.3400 USD to 1.690 USD: the price is 78.2% below the high and 8.3% above the low.

At a market capitalisation of 15.48M USD, it trades at 36.8 times trailing earnings. The median trailing P/E of its 19 largest Drug Manufacturers - General peers is 26.0, a premium of 41% for MIRA.

MIRA Pharmaceuticals reports return on equity of -100.5% and an operating margin of 0.0%.

It holds more cash than debt, a net cash position of 8.11M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.